Diagnostic Imaging

3 weeks ago | diagnosticimaging.com | Jeff Hall

Does washout timing play a significant role in differentiating between hepatoceullar carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC)? Can contrast-enhanced ultrasound (CEUS)-guided biopsies have an impact for liver lesions that elude characterization on B-mode ultrasound? Does CEUS provide more reliable detection of arterial phase hyper enhancement (APHE) in small HCC lesions than computed tomography (CT) and magnetic resonance imaging (MRI)?

3 weeks ago | diagnosticimaging.com | Jeff Hall

While some have predicted that artificial intelligence (AI) may replace radiologists, Samir Abboud, M.D., says generative AI will allow radiologists to maximize their time on image interpretation. In a new study, recently published in JAMA Network Open, Dr. Abboud and colleagues evaluated the impact of a generative AI model for providing initial drafts of radiology reports for radiographs.

3 weeks ago | diagnosticimaging.com | Jeff Hall

The Food and Drug Administration has granted 510(k) clearance for the Visualase V2 MRI-Guided Laser Ablation System, a minimally invasive alternative for performing soft tissue ablation in patients with radiation necrosis, focal epilepsy, or brain tumors.

3 weeks ago | diagnosticimaging.com | Jeff Hall

A new study suggests that artificial intelligence (AI) can significantly enhance the use of apparent diffusion coefficient (ADC) mapping in detecting prostate cancer (pCa) with magnetic resonance imaging (MRI). For the study, recently published in Academic Radiology, researchers assessed the impact of AI-generated ADC mapping from MRI to conventional ADC mapping in a cohort of 178 patients.

3 weeks ago | diagnosticimaging.com | Jeff Hall

The use of mid-treatment magnetic resonance imaging (MRI) may provide a pertinent glimpse of neoadjuvant chemotherapy outcomes in patients with triple-negative breast cancer (TNBC). In a new retrospective study, recently presented at the American Society of Clinical Oncology (ASCO) conference, researchers reviewed pre-, post- and mid-treatment MRI data and pathological outcomes for 154 patients treated with neoadjuvant chemotherapy for breast cancer.